Pacgen Completes Patient Recruitment for Phase IIb Trial of Antifungal Drug
Posted on: Wednesday, 16 April 2008, 09:01 CDT
Pacgen Biopharmaceuticals has completed the recruitment of patients in its Phase IIb dose-ranging clinical trial for PAC-113, a novel treatment for oral candidiasis infection. The company is on track to report final results from this study in June 2008.
The Phase IIb dose-ranging clinical trial is a randomized, examiner-blinded, parallel design trial comparing three different doses of PAC-113 to Nystatin, consisting of two week treatment phase and two week post-treatment or follow up phase. Nystatin is a widely used, topical mouth rinse treatment for oral Candidiasis.
PAC-113 is a peptide-based anti-fungal targeting oral candida infections in immunocompromised patients. The Phase IIb dose-ranging clinical trial of PAC-113 is being conducted at sites in the US and South Africa and has now successfully recruited over 200 seropositive HIV patients with oral candidiasis.
The trial will establish the efficacy for PAC-113 in eliminating clinical signs and symptoms of oral candidiasis, as well as provide an optimal dosing level for Phase III pivotal trials. Further safety and tolerance of PAC-113 administered orally and microbiological response of Candida albicans to PAC-113 will also be evaluated.
Source: Datamonitor
Related Articles
- RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
- Rexahn Pharmaceuticals Receives FDA Approval to Initiate Phase II Trial for Serdaxin in Patients With Major Depressive Disorders
- Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
- Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
- Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
- AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
- Exelixis Initiates Phase II Trial of XL880 in Patients With Gastric Cancer
- Targeted Genetics Presents Encouraging Interim Data From an Ongoing Phase I/II Trial of tgAAC94 in Patients With Inflammatory Arthritis
- Antisense Therapeutics Receives Approval to Restart Phase IIa Trial of ATL1102 for Patients With Multiple Sclerosis
- Enrollment Completed in Phase 2b Trial of Darusentan in Patients With Resistant Systolic Hypertension
 |
 |
User Comments (0)
RSS Feeds